Holen Sie sich die Stockscreener-App
513.36
0.42%
-2.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IDXX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$515.55
Offen:
$514.27
24-Stunden-Volumen:
1.32M
Relative Volume:
1.61
Marktkapitalisierung:
$41.28B
Einnahmen:
$3.93B
Nettoeinkommen (Verlust:
$894.97M
KGV:
47.45
EPS:
10.82
Netto-Cashflow:
$837.70M
1W Leistung:
+2.35%
1M Leistung:
+17.48%
6M Leistung:
+21.72%
1J Leistung:
+2.72%
1-Tages-Spanne:
$506.28
$515.92
1-Wochen-Bereich:
$505.81
$520.00
52-Wochen-Spanne:
$356.14
$530.60
Idexx Laboratories Inc Stock (IDXX) Company Profile
Firmenname
Idexx Laboratories Inc
Sektor
Branche
Telefon
(207) 556-0300
Adresse
ONE IDEXX DRIVE, WESTBROOK, ME
Vergleichen Sie IDXX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | BTIG Research | Buy |
| 2024-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-12-04 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-21 | Hochstufung | Goldman | Neutral → Buy |
| 2022-07-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-05-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-08 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-17 | Eingeleitet | Barclays | Overweight |
| 2019-09-09 | Eingeleitet | Goldman | Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Buy |
| 2018-11-02 | Bestätigt | BofA/Merrill | Buy |
| 2018-05-07 | Bestätigt | Stifel | Buy |
| 2018-01-16 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-08-23 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Hochstufung | CL King | Neutral → Buy |
| 2017-02-03 | Herabstufung | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Fortgesetzt | BofA/Merrill | Neutral |
| 2016-08-16 | Bestätigt | Stifel | Buy |
| 2016-08-03 | Hochstufung | Northcoast | Sell → Neutral |
| 2016-07-20 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-19 | Bestätigt | Canaccord Genuity | Buy |
| 2016-04-01 | Eingeleitet | CL King | Neutral |
| 2016-03-21 | Bestätigt | Stifel | Buy |
| 2016-02-04 | Eingeleitet | Credit Suisse | Outperform |
| 2015-10-29 | Bestätigt | Stifel | Buy |
| 2015-08-28 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Bestätigt | Stifel | Buy |
| 2015-07-23 | Bestätigt | Canaccord Genuity | Buy |
Alle ansehen
Idexx Laboratories Inc Aktie (IDXX) Neueste Nachrichten
Jim Cramer on IDEXX Laboratories, Inc. (IDXX): “I Just Can’t Get My Arms Around It” - Insider Monkey
Jim Cramer’s Thoughts on These 10 Stocks - Insider Monkey
Companion Animal Diagnostics Market Is Booming WorldwideIDEXX Laboratories, Heska Corporation - openPR.com
Transcript : IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference 2025, May-28-2025 10 - marketscreener.com
IDEXX Laboratories To Present At Stifel Jaws & Paws Conference; Webcast At 10:55 AM ET - Nasdaq
IDEXX Laboratories Stock: Analyst Estimates & Ratings - MSN
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
IDEXX Lab jumps after Q1 beat and guidance raise - MSN
IDEXX Laboratories (NASDAQ:IDXX) Given New $510.00 Price Target at Stifel Nicolaus - Defense World
IDEXX Laboratories (IDXX) Target Price Raised by Stifel to $510 | IDXX Stock News - GuruFocus
If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Idexx Laboratories (IDXX) Price Target Increased by Stifel Analy - GuruFocus
Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $460, Maintains Hold Rating - marketscreener.com
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits (NASDAQ:IDXX) - Seeking Alpha
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day | IDXX Stock News - GuruFocus
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day - Business Wire
BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $577 From $566, Maintains Outperform Rating - marketscreener.com
IDEXX Laboratories (NASDAQ:IDXX) Upgraded at StockNews.com - Defense World
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable - simplywall.st
Idexx outlines 2025 growth with 6-9% organic revenue target amid innovation launches - MSN
IDEXX Laboratories (IDXX) Announces Key Amendments to Corporate Structure - GuruFocus
IDEXX Laboratories Updates Corporate Governance Structure - TipRanks
Here’s Why Baron Focused Growth Fund Invested in IDEXX Laboratories (IDXX) - Insider Monkey
IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $558.00 at Morgan Stanley - Defense World
Rep. April McClain Delaney Buys IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock - Defense World
IDEXX Laboratories (IDXX) Target Price Raised by Morgan Stanley | IDXX Stock News - GuruFocus
BTIG Raises Price Target on IDEXX Laboratories to $545 From $530, Maintains Buy Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $558 From $548, Maintains Overweight Rating - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2025 Earnings Call Transcript - Insider Monkey
IDEXX Laboratories Ups Profit Forecast Thanks To Pet Care Demand - Finimize
IDEXX Laboratories [NasdaqGS:IDXX] Raises 2025 Guidance and Reports Q1 Growth in Revenue and EPS - Yahoo Finance
Leerink Partners Adjusts IDEXX Laboratories Price Target to $515 From $500 - marketscreener.com
IDEXX Laboratories Announces First Quarter Results | IDXX Stock News - GuruFocus
IDEXX Laboratories (IDXX) Surpasses Q1 Expectations with Robust Earnings - GuruFocus
IDEXX Laboratories Inc (IDXX) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid ... - Yahoo
IDEXX Laboratories Inc (IDXX) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid Market Challenges - GuruFocus
IDEXX Laboratories Reports Strong Q1 2025 Results - TipRanks
Idexx: Q1 Earnings Snapshot - CT Insider
IDEXX Laboratories’ Earnings Call: Strong Growth Amid Challenges - TipRanks
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) CEO Compensation Looks Acceptable To Us And Here's Why - simplywall.st
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
Stifel Adjusts Price Target for Idexx Laboratories (IDXX) Following Q1 Results | IDXX Stock News - GuruFocus
IDEXX Laboratories (IDXX) Surges After Lifting 2025 Outlook on F - GuruFocus
IDEXX Laboratories stock jumps on Q1 beat (IDXX:NASDAQ) - Seeking Alpha
Finanzdaten der Idexx Laboratories Inc-Aktie (IDXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Idexx Laboratories Inc-Aktie (IDXX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SZOSTAK M ANNE | Director |
May 21 '25 |
Sale |
512.34 |
1,260 |
645,545 |
1,801 |
| SZOSTAK M ANNE | Director |
May 21 '25 |
Sale |
513.74 |
1,046 |
537,372 |
262 |
1.20%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):